OBJECTIVE
To analyse Rituximab’s off-label indications as well as the treatment schedule used to evaluate the degree of compliance with the Royal Decree which regulates the use of medicines under special circumstances.

MATERIAL AND METHODS
Observational, retrospective study

Population

Patients treated with Rituximab, both exclusively or in combination with other drugs

Variables

☑ Age
☑ Gender
☑ Diagnosis
☑ Treatment received
☑ Off-label indication?

Data collection

Oncofarm®
Selene 5.3 SP08®
Processed and authorised by the Medical Board at the hospital?

RESULTS

78 patients, 103 treatments

51% women
49% men
Average age: 69 years

Treatment schedules

48%
22%
13.5%
12.5%
Others

R-CHOP
R every 2 months
R quarterly

42% were not processed

OFF-LABEL INDICATIONS

Membranous glomerular nephropathy 14.5%
CLL as maintenance treatment 12.5%
Mantle cell lymphoma 10.5%
Waldenström’s macroglobulinemia 10.5%

CONCLUSIONS

Prescribing Rituximab for off-label indications is very frequent in hospitals. These situations should be registered under some therapeutic protocols, mandatory for physicians, and in which regulation the Pharmaceutical and Therapeutical Commission should be actively engaged and involved.